Evidence map›Paper›PMID 42220498›Full record

ReviewFrontiers in immunology2026

Circular RNAs as diagnostic biomarkers in type 2 diabetes mellitus: implications in metabolic dysfunction and immune-inflammatory crosstalk.

Zhaoxia Liu, Hui Wu, Qiaoshuang Pu, Xiongtao Yang, Da Li, Shipin Feng, Yan Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhaoxia LiuGeneral Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Hui WuGeneral Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Qiaoshuang PuGeneral Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Xiongtao YangGeneral Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Da LiGeneral Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Shipin FengDepartment of Pediatric Nephrology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yan WangGeneral Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolically heterogeneous disease for which current approaches to early diagnosis and risk stratification remain limited. Circular RNAs (circRNAs) have emerged as promising molecular candidates because of their stability, disease relevance, and regulatory versatility. Circular RNAs (circRNAs) have emerged as a promising class of non-coding RNAs that exhibit unique advantages, such as high stability, disease specificity, and the ability to act as regulators in competing endogenous RNA (ceRNA) networks. This review summarizes the current understanding of circRNAs in T2DM, highlighting their potential as diagnostic biomarkers and their roles in metabolic dysfunction. We explore how circRNAs contribute to key pathogenic processes in T2DM, including insulin resistance, glucose uptake, β-cell survival, inflammation, and vascular dysfunction. Additionally, we discuss the challenges in circRNA research, including technical biases, cohort heterogeneity, and the need for rigorous mechanistic validation. The review concludes by outlining future directions for circRNA-based research, including multicenter prospective studies, single-cell and spatial transcriptomic integration, and the development of circRNA-based companion diagnostics for precision medicine in T2DM.

Indexed as

Diabetes Mellitus, Type 2RNA, CircularAnimalsBiomarkersHumansInflammationInsulin ResistanceRNA, Competitive EndogenousBiomarkersRNA, CircularRNA, Competitive Endogenouscircular RNAscompeting endogenous RNA (ceRNA)diagnostic biomarkersmetabolic dysfunctiontype 2 diabetes mellitus

Identifiers

PMID42220498
PMCPMC13218905

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.